Poolbeg PharmaPOLBF -20.36% Quick Ratio is 6.17 as of Dec. 2025, which is 55% below its 10-year median of 13.69. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Poolbeg Pharma ranks better than 65.98% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Poolbeg Pharma's quick ratio for the quarter that ended in Dec. 2025 was 6.17.
Poolbeg Pharma has a quick ratio of 6.17. It generally indicates good short-term financial strength.
The historical rank and industry rank for Poolbeg Pharma's Quick Ratio or its related term are showing as below:
POLBF'
s Quick Ratio Range Over the Past 10 Years
Min: 6.17 Med: 13.69 Max: 48.98
Current: 6.17
During the past 5 years, Poolbeg Pharma's highest Quick Ratio was 48.98. The lowest was 6.17. And the median was 13.69.
POLBF's Quick Ratio is ranked better than 65.98% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs POLBF: 6.17
Poolbeg Pharma (OTCPK:POLBF) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Poolbeg Pharma Quick Ratio Related Terms
Poolbeg Pharma Quick Ratio Historical Data
* Premium members only.
The historical data trend for Poolbeg Pharma's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Poolbeg Pharma's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Poolbeg Pharma Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Poolbeg Pharma's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Poolbeg Pharma's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Poolbeg Pharma's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Poolbeg Pharma (POLBF) has a Quick Ratio of 6.17 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Poolbeg Pharma and its competitors. This is 55% below median its historical median of 13.69. Over the past decade, Poolbeg Pharma's Quick Ratio has ranged from 6.17 to 48.98. According to the industry distribution chart, Poolbeg Pharma ranks #482 out of 1417 companies in the Biotechnology industry, placing it in the top 34%.
Is Poolbeg Pharma's Quick Ratio too high?
Poolbeg Pharma's current Quick Ratio of 6.17 is 55% below median its 10-year median of 13.69. Over the past 10 years, this metric has ranged from a low of 6.17 to a high of 48.98. The Biotechnology industry median Quick Ratio is 3.60. Poolbeg Pharma's value of 6.17 is 71.4% above this industry median. Based on the distribution chart, Poolbeg Pharma ranks #482 out of 1417 companies in the Biotechnology industry, which is above the industry midpoint.
How does Poolbeg Pharma's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Poolbeg Pharma ranks #482 out of 1417 companies for Quick Ratio. This puts Poolbeg Pharma in the upper half of its industry. The industry median Quick Ratio is 3.60. Poolbeg Pharma's value of 6.17 is 71.4% above this benchmark. Historically, Poolbeg Pharma's own Quick Ratio has ranged from 6.17 to 48.98 over the past decade. While the company's 10-year median is 13.69 vs. the industry median of 3.60, Poolbeg Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Poolbeg Pharma's current Quick Ratio of 6.17 is 71.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Poolbeg Pharma and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Poolbeg Pharma's current Quick Ratio is 6.17, which is 55% below median its own 10-year median of 13.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Quick Ratio of 6.17. The current Quick Ratio is 6.17, which is 55% below median its 10-year median of 13.69 and 71.4% above the Biotechnology industry median of 3.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Quick Ratio is 6.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
POLBF has been successfully added to your 